Update date
30 Jun 2025
Shareable Research Card
ADXN - Addex Therapeutics Ltd. Assets
This metric view shows ADXN - Addex Therapeutics Ltd. assets history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q2 2025
- Latest reported value
- CHF8,506,015
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 30 Jun 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q2 2025.
- Latest reported value on this page: CHF8,506,015.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Assets
Latest reported assets: CHF8,506,015. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q2 2025
SEC-backed company facts were refreshed from filings filed on 30 Sep 2025.
Benchmark Context
How Assets compares with peers
Addex Therapeutics Ltd. sits in the bottom quarter of the current assets sample.
Compared with
Compared with 8 companies reporting assets in CHF. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.1x the current sample midpoint. Assets does not yet have enough prior-period data for a historical comparison on this page.
- Visible rows currently span reported period ends from 31 Dec 2023 to 31 Dec 2025.
- Nearby companies in this sample: MindMaze Therapeutics Holding SA and Altamira Therapeutics Ltd..
- Current sample position: rank #7 of 8 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Addex Therapeutics Ltd.: Assets
Latest period: Q2 2025. Period end: 30 Jun 2025. Units: CHF. Frequency: quarterly.
Assets is reported in company XBRL facts filed with the SEC.
Metric snapshot
- Latest value
- CHF8,506,015
- Coverage range
- 31 Dec 2021 - 30 Jun 2025
- Fact rows
- 7
What this metric tells you
- Shows reported assets over 31 Dec 2021 - 30 Jun 2025.
- Use consecutive periods in the table to assess trend direction when YoY change is unavailable.
- Built from 7 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View financial facts overview
- Addex Therapeutics Ltd. SEC filings
- Latest 10-Q/10-K hub
- Open SEC company facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Assets levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Addex Therapeutics Ltd. appears at rank #7 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | Sunrise Communications AG (snnrf) | CHF12,062,800,000 | Instant - 31 Dec 2024 | Open Sunrise Communications AG Assets |
| 2 | On Holding AG (onon) | CHF2,835,400,000 | Instant - 31 Dec 2025 | Open On Holding AG Assets |
| 3 | Oculis Holding AG (ocs) | CHF235,963,000 | Instant - 31 Dec 2025 | Open Oculis Holding AG Assets |
| 4 | AC Immune SA (aciu) | CHF154,251,000 | Instant - 31 Dec 2025 | Open AC Immune SA Assets |
| 5 | MOLECULAR PARTNERS AG (moln) | CHF102,107,000 | Instant - 31 Dec 2025 | Open MOLECULAR PARTNERS AG Assets |
| 6 | MindMaze Therapeutics Holding SA | CHF76,390,000 | Instant - 31 Dec 2023 | Open MindMaze Therapeutics Holding SA Assets |
Metric Details
- Metric
- Assets (Assets)
- Frequency coverage
-
quarterly
Comparability: Compare annual with annual and quarterly with quarterly
- Taxonomy
- ifrs-full
- Units tracked
- CHF
- History range
-
31 Dec 2021 - 30 Jun 2025
Freshness: From parsed SEC XBRL facts on this page
- Facts on this page
-
7
Source: SEC company facts API
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Assets, Quarterly (CHF)
Assets, YoY Quarterly Change (%)
Addex Therapeutics Ltd. Quarterly Assets (CHF)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | CHF8,506,015 | 30 Jun 2025 | 6-K | 30 Sep 2025 | 2025 | Q2 | ||
| Q4 2024 | CHF10,678,303 | +CHF6,036,418 | +130% | 31 Dec 2024 | 6-K | 30 Sep 2025 | 2025 | Q2 |
| Q4 2023 | CHF4,641,885 | -CHF3,640,165 | -44% | 31 Dec 2023 | 20-F | 15 May 2025 | 2024 | FY |
| Q2 2023 | CHF8,998,443 | -CHF2,383,606 | -21% | 30 Jun 2023 | 6-K/A | 21 Dec 2023 | 2023 | Q2 |
| Q4 2022 | CHF8,282,050 | -CHF14,259,734 | -63% | 31 Dec 2022 | 20-F | 18 Apr 2024 | 2023 | FY |
| Q2 2022 | CHF11,382,049 | 30 Jun 2022 | 6-K/A | 14 Sep 2022 | 2022 | Q2 | ||
| Q4 2021 | CHF22,541,784 | +CHF2,359,972 | +12% | 31 Dec 2021 | 20-F | 30 Mar 2023 | 2022 | FY |
* marks a reported value that did not pass the local value check.